We previously showed that the small GTPase ARF6 and its effector AMAP1 are often overexpressed in different types of cancers, including breast cancer and renal cancer, and play pivotal roles in promoting invasion, metastasis, and drug resistance [6–18]. Here, ARF6 is linked to renal carcinoma.